[Small cell lung cancer and immuno-oncologic agents: End of the cisplatin - etoposide era?]

Area of Science:

• Oncology
• Immunotherapy

Background:

• Small cell lung cancer (SCLC) treatment options remain limited.
• Immuno-oncology agents targeting Programmed cell Death protein 1 (PD-1) and Programmed cell Death protein Ligand 1 (PD-L1) are emerging therapies.

Purpose of the Study:

• To review the current status of PD-1/PD-L1 inhibitors in SCLC.
• To identify challenges and future directions for immuno-oncology in SCLC.

Main Methods:

• Analysis of existing Phase I and Phase II clinical trial data for PD-1/PD-L1 inhibitors in SCLC.
• Review of literature regarding predictive factors for treatment response.

Main Results:

• Current data are primarily from early-phase trials (Phase I/II), lacking Phase III evidence.
• Limited progress in identifying predictive biomarkers for patient response.
• Promising trends in progression-free survival observed in Phase II studies.

Conclusions:

• The development of PD-1/PD-L1 inhibitors in SCLC is in its early stages.
• Fragmentary clinical data preclude definitive recommendations.
• Further research, including Phase III trials and biomarker development, is crucial for advancing SCLC treatment.